OBJECTIVE: We evaluated regional brain volumes and cerebral metabolite levels as correlates of HIV DNA in peripheral blood mononuclear cells (PBMCs). METHODS: In this cross-sectional study, 35 HIV+ subjects aged ≥40 years (25 with detectable PBMC HIV DNA; 10 with HIV DNA <10 copies/10(6) cells, the threshold of detection) and 12 seronegative controls underwent structural brain MRI and magnetic resonance spectroscopy at 3 T. HIV+ subjects were on combination antiretroviral therapy ≥1 year; all but 1 had plasma HIV RNA <50 copies/mL. We used logistic regression to evaluate relationships of likely predictor variables to the outcome of PBMC HIV DNA detectability in the HIV+ subjects. Effects of serostatus and HIV DNA on regional brain volumes (normalized to intracranial volume) and on metabolite ratios over creatine were evaluated by analyses of covariance, controlling for age. RESULTS: Relative to the HIV+ group with undetectable HIV DNA, subjects with detectable HIV DNA demonstrated decreased volumes of cerebellar (-14%, p = 0.020) and total subcortical (-10%, p = 0.024) gray matter. Compared to healthy controls, only the detectable HIV DNA group showed significant (p < 0.05) enlargement of lateral ventricles and volumetric reductions of caudate, putamen, thalamus, hippocampus, nucleus accumbens, brainstem, total cortical gray matter, and cerebral white matter. Detectable HIV DNA was not associated with significantly altered cerebral metabolite levels. CONCLUSION: Inability to clear peripheral blood of HIV DNA is associated with regional brain atrophy in well-controlled HIV infection, supporting the involvement of peripheral viral reservoirs in the neuropathogenesis of persistent HIV-related neurocognitive disorders.
OBJECTIVE: We evaluated regional brain volumes and cerebral metabolite levels as correlates of HIV DNA in peripheral blood mononuclear cells (PBMCs). METHODS: In this cross-sectional study, 35 HIV+ subjects aged ≥40 years (25 with detectable PBMC HIV DNA; 10 with HIV DNA <10 copies/10(6) cells, the threshold of detection) and 12 seronegative controls underwent structural brain MRI and magnetic resonance spectroscopy at 3 T. HIV+ subjects were on combination antiretroviral therapy ≥1 year; all but 1 had plasma HIV RNA <50 copies/mL. We used logistic regression to evaluate relationships of likely predictor variables to the outcome of PBMC HIV DNA detectability in the HIV+ subjects. Effects of serostatus and HIV DNA on regional brain volumes (normalized to intracranial volume) and on metabolite ratios over creatine were evaluated by analyses of covariance, controlling for age. RESULTS: Relative to the HIV+ group with undetectable HIV DNA, subjects with detectable HIV DNA demonstrated decreased volumes of cerebellar (-14%, p = 0.020) and total subcortical (-10%, p = 0.024) gray matter. Compared to healthy controls, only the detectable HIV DNA group showed significant (p < 0.05) enlargement of lateral ventricles and volumetric reductions of caudate, putamen, thalamus, hippocampus, nucleus accumbens, brainstem, total cortical gray matter, and cerebral white matter. Detectable HIV DNA was not associated with significantly altered cerebral metabolite levels. CONCLUSION: Inability to clear peripheral blood of HIV DNA is associated with regional brain atrophy in well-controlled HIV infection, supporting the involvement of peripheral viral reservoirs in the neuropathogenesis of persistent HIV-related neurocognitive disorders.
Authors: Bruce Fischl; André van der Kouwe; Christophe Destrieux; Eric Halgren; Florent Ségonne; David H Salat; Evelina Busa; Larry J Seidman; Jill Goldstein; David Kennedy; Verne Caviness; Nikos Makris; Bruce Rosen; Anders M Dale Journal: Cereb Cortex Date: 2004-01 Impact factor: 5.357
Authors: Z G Jiang; C Piggee; M P Heyes; C Murphy; B Quearry; M Bauer; J Zheng; H E Gendelman; S P Markey Journal: J Neuroimmunol Date: 2001-07-02 Impact factor: 3.478
Authors: N Sacktor; R H Lyles; R Skolasky; C Kleeberger; O A Selnes; E N Miller; J T Becker; B Cohen; J C McArthur Journal: Neurology Date: 2001-01-23 Impact factor: 9.910
Authors: C Ferrarese; A Aliprandi; L Tremolizzo; L Stanzani; A De Micheli; A Dolara; L Frattola Journal: Neurology Date: 2001-08-28 Impact factor: 9.910
Authors: Randy L Buckner; Denise Head; Jamie Parker; Anthony F Fotenos; Daniel Marcus; John C Morris; Abraham Z Snyder Journal: Neuroimage Date: 2004-10 Impact factor: 6.556
Authors: I Elovaara; E Poutiainen; R Raininko; L Valanne; A Virta; S L Valle; J Lähdevirta; M Iivanainen Journal: J Neurol Sci Date: 1990-11 Impact factor: 3.181
Authors: Sarah L Archibald; Eliezer Masliah; Christine Fennema-Notestine; Thomas D Marcotte; Ronald J Ellis; J Allen McCutchan; Robert K Heaton; Igor Grant; Margaret Mallory; Aida Miller; Terry L Jernigan Journal: Arch Neurol Date: 2004-03
Authors: C Paula Lewis-de Los Angeles; Paige L Williams; Yanling Huo; Shirlene D Wang; Kristina A Uban; Megan M Herting; Kathleen Malee; Ram Yogev; John G Csernansky; Sharon Nichols; Russell B Van Dyke; Elizabeth R Sowell; Lei Wang Journal: Brain Behav Immun Date: 2017-01-10 Impact factor: 7.217
Authors: Aditya N Bade; Santhi Gorantla; Prasanta K Dash; Edward Makarov; Balasrinivasa R Sajja; Larisa Y Poluektova; Jiangtao Luo; Howard E Gendelman; Michael D Boska; Yutong Liu Journal: Mol Neurobiol Date: 2015-06-11 Impact factor: 5.590
Authors: Adolf Pfefferbaum; Natalie M Zahr; Stephanie A Sassoon; Dongjin Kwon; Kilian M Pohl; Edith V Sullivan Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2018-07-04